Why Pharmacopoeia Compliance Is Difficult–An End-to-End Compendial Framework (PDF)

This article provides an end-to-end compendial framework to understand why compliance with pharmacopoeia standards is challenging.

Related Content:

Regulatory Oversight and ComplianceQuality Assurance/Quality ControlQuality Systems

Ask the Expert: Adventitious Contamination Control

European Pharmacopoeia Goes Digital

Six Biosimilars Part of EMA’s Authorization Recommendations in June